Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer
10.3971/j.issn.1000-8578.2022.22.0064
- VernacularTitle:临界可切除胰腺癌新辅助治疗研究进展
- Author:
Zegang CHEN
1
;
Yongbing WANG
;
Tao OU
Author Information
1. Department of Oncology, Chongqing Liangping District People's Hospital, Chongqing 405200, China
- Publication Type:Research Article
- Keywords:
Pancreatic ductal adenocarcinoma;
Borderline resectable pancreatic cancer;
Neoadjuvant therapy;
Operation;
Chemotherapy;
Radiotherapy
- From:
Cancer Research on Prevention and Treatment
2022;49(9):982-986
- CountryChina
- Language:Chinese
-
Abstract:
Borderline resectable pancreatic ductal adenocarcinoma accounts for approximately 20% of newly diagnosed pancreatic cancer patients. This type of adenocarcinoma is between resectable and unresectable. It has a high degree of heterogeneity and features in anatomy, biology, and physical condition. The biological characteristics of invasiveness determine that, rather than direct surgery, neoadjuvant therapy should be primarily given to patients to achieve R0 resection and avoid early postoperative recurrence. However, this treatment model is still controversial. According to the latest research on this topic, the full text summarizes the definition of BR-PDAC, resectable evaluation, neoadjuvant treatment selection and evaluation, surgical results after neoadjuvant therapy, and the efficacy of adjuvant therapy after neoadjuvant therapy.
